RAF1 and neoplasm: In this study we demonstrate that the combination of the investigational selective small molecule inhibitor of monomer and dimer forms of RAF, brimarafenib, in combination with the investigational selective and non‐ATP comparative MEK inhibitor mirdametinib, shows additive anti‐tumor efficacy in vitro and in vivo.